Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile

Table 1

Characteristics of Crohn’s disease patients studied: both responders () and nonresponders () to infliximab.

	Responders		Nonresponders		value
		%		%
Age	39.6 ± 0.7		41.9 ± 1.5		0.10
Sex
Male	135	47.4	26	41.9	0.44
Female	150	52.6	36	58.1
Years of disease	10.2 ± 0.4		13.2 ± 1.1		0.0067
Age at diagnosis (A)
A1	36	12.9	8	13.1	0.61
A2	203	72.5	47	77.1
A3	41	14.6	6	9.8
Location (L)
L1	74	26.5	28	46.6	0.014^a
L2	57	20.4	8	13.4
L3	137	49.1	24	40.0
L4	2	0.7	0	0
L1 + L4	3	1.1	0	0
L2 + L4	1	0.4	0	0
L3 + L4	5	1.8	0	0
Behavior (B)
B1	79	28.2	19	31.7	0.56
B2	27	9.6	7	11.7
B3	46	16.5	11	18.3
B1p	70	25.0	8	13.3
B2p	9	3.2	2	3.3
B3p	49	17.5	13	21.7

Data correspond at first IFX dose.
A1: ≤16 years; A2: 17–40 years; A3: >40 years. L1: terminal ileum; L2: colon; L3: ileocolon; L4: upper GI; L1 + L4: terminal ileum + upper GI; L2 + L4: colon + upper GI; L3 + L4: ileocolon + upper GI. B1: nonstricturing, nonpenetrating; B2: structuring; B3: penetrating; B1p: nonstricturing, nonpenetrating + perianal; B2p: structuring + perianal; B3p: penetrating + perianal.
^aExcluding categories with L4.